Note the Trofinetide trial was with 82 participants, and placebo controlled. The first 14 days (D14) obtained baseline data, and the full study was for 54 days (D54). The Anavex study was 6 patients, no placebo.
The 200mg/kg dose arm shows Trofinetide RSBQ score dropping 6.7, while the placebo arm drops 2.3.
Comparing these to the Anavex scores that dropped 16 points, we can see: 1) A2-73 provided a much stronger signal, >2x that of Trofinetide! 2) The placebo affect accounts for a drop of only 2.3 points. Assuming similar placebo affect with A2-73, there is still a very strong signal, two times as strong as Trofinetide!
What is called placebo response is in many cases the normal variation in symptoms over time. That is part of what a placebo arm does. It captures the variability is symptoms over time.
Everyone has good days and bad days, catches a cold, gets a virus or has a cold or virus when baseline data is taken. There seems to be an assumption that Rett symptoms are a constant, I strongly doubt that is true.
News 
Market Data 
Discover 
